Form 4: CytomX Therapeutics CFO Christopher Ogden Reports Stock Transactions
SEC Form 4 Filing
Christopher Ogden, CFO of CytomX Therapeutics, reports the vesting of performance stock units and subsequent sale of shares to cover tax obligations.
Summary
- On August 20, 2024, Christopher Ogden, the Chief Financial Officer of CytomX Therapeutics, executed transactions involving the company's common stock.
- Ogden vested 6,875 Performance Stock Units (PSUs), each representing a contingent right to receive one share of CytomX's common stock.
- Following the vesting, Ogden sold 1,984 shares at a price of $1.2291 per share.
- This sale was solely to satisfy tax or other government withholding obligations related to the PSU vesting.
- After these transactions, Ogden beneficially owns 108,077 shares of CytomX Therapeutics common stock, which includes 77,810 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade their company's stock. This provides transparency to the market regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| 08/10/2022 | Initial grant date of the Performance Stock Unit (PSU) award. |
| 12/17/2023 | 50% of the PSUs vested upon achievement of a performance-based milestone. |
| 08/20/2024 | Date of PSU vesting and stock sale by Christopher Ogden. |
| 08/22/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.